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Abstract Patients with cardiovascular disease (CVD) are a
heterogeneous group regarding their bodymass index (BMI)
levels at the time of diagnosis. To address the heterogeneity
of CVD, we examined the trajectories of change in body
mass index (BMI) and in other cardio-metabolic risk factors
before CVD diagnosis. The study included 6126 participants
from the prospective population-based Rotterdam Study,
followed over 22 years with clinical examinations every
4 years. Latent class trajectory analysis and mixed-effect
models were used to develop trajectories of BMI and other
cardio-metabolic risk factors respectively. During follow-
up, 1748 participants developed CVD, among whom we
identified 3 distinct BMI trajectories. The majority of par-
ticipants (n = 1534, 87.8 %) had steady BMI levels during
follow-up, comprising the ‘‘stable weight’’ group. This
group showed decrease in mean high-density lipoprotein
(HDL) cholesterol over time. The second group, the
‘‘progressive weight gain’’ group (n = 112, 6.4 %), showed
a progressive increase in BMI levels. In this group, mean
waist circumference increased, mean HDL cholesterol
decreased and mean fasting glucose levels were fluctuating
over follow-up. In the third group, the ‘‘progressive weight
loss’’ group (n = 102, 5.8 %), BMI levels decreased during
follow-up. This group showed a decrease in mean waist
circumference and in fasting glucose. In conclusion, the
majority of individuals who developed CVD had a
stable weight during follow-up, suggesting that BMI alone is
not a good indicator for identifying middle-aged and elderly
individuals at high risk of CVD. Waist circumference, HDL
cholesterol, and glucose trajectories differed between the
identified BMI subgroups, further highlighting that CVD is a
heterogeneous disease with different pathophysiological
pathways.
Keywords Obesity/physiopathology  Cardiovascular
disease  Body mass index  Blood pressure  Lipids 
Glucose
Introduction
The association between obesity and cardiovascular dis-
ease (CVD) has been well established in observational
studies [1, 2]. The causality of this relationship has also
been recently reported using a Mendelian randomization
approach [3]. Additionally, duration of obesity has been
shown to be a risk factor for CVD [4, 5], diabetes [6], and
mortality [7], independent of the baseline levels of body
mass index (BMI). However, CVD is not only limited to
obese individuals, and normal weight or overweight indi-
viduals may also experience a cardiovascular event [8, 9].
Consequently, patients with CVD are a heterogeneous
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group with regard to their BMI levels at the time of diag-
nosis of CVD. Understanding the heterogeneity of CVD by
exploring the distinct patterns of change in BMI levels
prior to the diagnosis of CVD might carry important
implications for improving disease prevention or treatment.
For instance, each trajectory of BMI change prior to CVD
could be accompanied by different trajectories of change in
other cardio-metabolic risk factors. As such, identification
of different population subgroups with similar risk factor
patterns might serve to facilitate targeted cardiovascular
prevention programs.
One way of exploring this heterogeneity is to group
individuals with similar patterns of change in BMI over
time through data-driven statistical methods such as latent
class trajectory analysis [10]. Latent class trajectory anal-
ysis is an innovative statistical method used to identify
subgroups (classes) of participants who are homogeneous
with respect to the trajectory of one specific risk factor but
heterogeneous as compared with other subgroups. Latent
class trajectory analysis has recently been applied to study
BMI development prior to diagnosis of diabetes [11].
In the current study among a middle-aged and elderly
population, we aimed to identify different trajectories of
BMI development prior to a cardiovascular event. We also
sought to explore the trajectories of concurrent cardio-
metabolic risk factors, including blood pressure, lipids, and
glucose, within each identified BMI subgroup.
Methods
Study population
The Rotterdam Study (RS) is a prospective population-
based cohort study. In 1989–1993, the original cohort (RS-
I) recruited 7983 (78 % response rate) men and women
aged 55 years and older from a well-defined suburb in the
city of Rotterdam, the Netherlands. The participants of the
Rotterdam Study have been followed-up for more than
22 years and the clinical data have been collected across
five subsequent phases, approximately 4 years apart. Each
phase of the study included a home interview followed by
two visits at the research center for clinical examinations.
Details regarding the objectives and design of the Rotter-
dam Study have been reported previously [12].
The present analysis was based on the original cohort
(RS-I). From 7983 subjects participating at baseline, we
excluded 225 participants without informed consent, 963
individuals with prevalent CVD (including: myocardial
infraction (MI), coronary heart disease (CHD), heart fail-
ure, and stroke), 646 individuals without BMI measure-
ments throughout phases 1–5, and 23 participants without
information regarding CVD follow-up. Thus, the final
sample included 6126 participants (77 % of original sam-
ple) (Fig. 1).
Assessment of cardio-metabolic risk factors
Information on cardio-metabolic risk factors was collected
through home interviews or measured at the study center
visit as described previously [13, 14]. Height and weight
were measured in all five phases, whereas systolic blood
pressure and waist circumference were measured in phases
1, 3, 4 and 5, and fasting total cholesterol, high-density
lipoprotein (HDL) cholesterol and fasting plasma glucose
were measured in phases 3, 4 and 5 (Fig. 1). Height and
weight were measured with the participants standing
without shoes and heavy outer garments. BMI was calcu-
lated as weight divided by height squared (kg/m2). Waist
circumference was measured at the level midway between
the lower rib margin and the iliac crest with participants in
standing position without heavy outer garments and with
emptied pockets, breathing out gently. Serum total
cholesterol, HDL cholesterol, and glucose were measured
using standard laboratory techniques. Blood pressure was
measured at the right brachial artery with a random-zero
sphygmomanometer with the participant in sitting position,
and the mean of two consecutive measurements was used.
Smoking status was classified as current smoking or others
(former and never) in all phases. We assessed medication
use for hypertension, hyperlipidemia and diabetes mellitus
through interview.
Clinical outcome
The main outcome measure was incident CVD [15],
composed of coronary heart disease (CHD) [13] and stroke
[16]. CHD was composed of fatal and non-fatal myocardial
infarction and other CHD mortality. Stroke was composed
of fatal and non-fatal stroke. Data on incident CVD were
collected through an automated follow-up system and by
gathering information from general practitioners working
in the study area until January 1, 2012.
Statistical analysis
Our statistical analysis included two consequent steps.
Initially, we used latent class trajectory analysis to identify
groups of participants with distinct trajectories of BMI
change during follow-up, until the occurrence of the first
cardiovascular event [10]. Subsequently, within each
identified BMI group, we developed the trajectories of
change in other cardio-metabolic risk factors during the
follow-up [11].
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The latent class trajectory analysis automatically divides
the study population into classes, in such a way that par-
ticipants in the same class tend to have similar trajectories
of BMI change. By design of the study we performed this
analysis only in the population diagnosed with CVD during
follow-up. Therefore, the observation period for the
development of trajectories started retrospectively at the
date of diagnosis with CVD. For the subjects within each
group, the latent class trajectory model assumes that the
BMI measurements follow a linear mixed-effects model
with BMI as the dependent variable and time before CVD
diagnosis (time 0), age, sex and phase of study as inde-
pendent variables. The independent variable ‘‘time before
CVD diagnosis’’ was used to describe the shape of the
longitudinal trajectory of BMI, using a cubic specification
(i.e., linear, quadratic, and cubic terms for the time before
CVD diagnosis were entered as covariates into the model).
The Bayesian information criterion (BIC) was used to
choose the number of classes in the latent class trajectory
model. The latent class trajectory model calculates a pos-
terior probability of membership in each latent class for
each participant. Each participant is assigned to the class
for which his/her posterior probability is the highest. To
ensure that all obtained classes were of clinically mean-
ingful size, we imposed the condition that each class
should include at least 5 % of participants and the mean
posterior probability of each class should be higher than
75 %. Since the trajectories of change in BMI could differ
between individuals who die during follow-up and among
individuals who do not die or develop CVD during follow-
up [17] we divided the rest of the population into two
subgroups: (1) CVD-free and alive until end of follow-up
and (2) non-CVD mortality.
For each identified BMI group (among individuals
diagnosed with CVD) and the two other groups (CVD-free,
and non-CVD mortality), we examined the trajectories in
other cardio-metabolic risk factors including waist cir-
cumference; systolic and diastolic blood pressure; fasting
total and HDL cholesterol; and fasting plasma glucose.
Since the aggregated effect of combined risk factors on
CVD might differ from each risk factor alone or from
merely sum of risk factors, guidelines recommend to
evaluate the 10-year CVD risk of an individual in clinical
practice [18]. Therefore, we examined the trajectories of
10-year CVD risk in each group of BMI. The predicted
10-year CVD risk was calculated using the American
College of Cardiology/American Heart Association (ACC/
AHA) Pooled Cohort Equation coefficients, which includes
age, sex, total cholesterol, HDL cholesterol, systolic blood
pressure, blood pressure lowering medication use, diabetes
Roerdam Study, Cohort I
n=7983
Excluded n=1857 parcipants  
225 no informant consent
963 prevalent CVD
646 no measured BMI throughout study
23 no follow-up informaon
Measures included in the study
Body mass index (Phase 1, 2, 3, 4, 5)
Waist circumference (Phase 1, 3, 4, 5)
Systolic and diastolic blood pressure (Phase 1, 3, 4, 5)
Total and HDL cholesterol* (Phase 3, 4, 5)
Glucose* (Phase 3, 4, 5)
Phase 1 (RS-I-1)
n=6126
Phase 2 (RS-I-2)
n=4982
Phase 3 (RS-I-3)
n=3702
Phase 4 (RS-I-4)
n=2549
Phase 5 (RS-I-5)
n=1062
Fig. 1 Flow diagram of the
participants included at each
phase. HDL high density
lipoprotein, CVD cardiovascular
disease, n number. * Total
cholesterol, HDL cholesterol
and glucose are measured as
fasting in phases 3, 4 and 5
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status, and smoking status in the prediction model [15].
These trajectories of cardio-metabolic risk factors were
estimated using linear mixed-effects models. The inde-
pendent variables in these linear mixed-effects models
were follow-up time, age, sex, and study phase. Analyses
of lipids were further adjusted for lipid-lowering treatment,
analyses of blood pressure were further adjusted for anti-
hypertensive treatment, and analyses of glucose were
additionally adjusted for diabetes treatment. Quadratic and
cubic terms for follow-up time were included in the BMI
groups (latent classes) when significant (p\ 0.05). For
individuals not developing CVD during follow-up (CVD-
free and non-CVD mortality groups), year 0 is merely a
time point in a normal life course, and we therefore fitted
the trajectories by using linear models. Pair-wise differ-
ences in growth curves between BMI groups were tested
using F-tests for each cardio-metabolic risk factor. Paired
Chi square test (for categorical variables) was used to
compare participant characteristics between the groups. To
account for multiple testing due to comparing three pairs of
BMI groups, we used a Bonferroni-adjusted significance
level of 0.05/3 = 0.0167 for the F-tests for each cardio-
metabolic risk factor. All other statistical tests used a sig-
nificance level of 0.05, and all statistical tests were two-
sided.
Analyses were conducted using R statistical software,
version 3.0.1 (R Foundation for Statistical Computing,
Vienna, Austria), with the package ‘‘lcmm’’ [10].
Results
Baseline characteristics of the study population are pre-
sented in Table 1. Overall, 6126 participants with a mean
age of 68.8 years, mostly women (n = 3787, 61.8 %), and
overweight (mean BMI = 26.3) were included in the study
(Table 1). The median (interquartile range—IQR) of total
follow-up was 14.7 (7.6; 18.3) years during which 28.5 %
of participants (n = 1748) developed CVD. Among indi-
viduals who did not develop CVD, 2184 subjects (35.7 %)
remained alive until the end of follow-up and 2194
(35.8 %) died from non-CVD causes. The baseline char-
acteristics of these subgroups are presented in Table S1 in
the Supplementary Material.
Patterns of BMI change over time
Among 1748 participants who developed CVD, we identi-
fied three groups with distinct trajectories of change in BMI
levels. The largest group of individuals (n = 1534, 87.8 %)
was classified in the first group and showed stableBMI levels
over time. This group entered the study with an average BMI
of 25.6 kg/m2 and maintained this average BMI level during
follow-up. Therefore, we named this group ‘‘stable weight’’.
The second group comprised 112 (6.4 %) individuals who
entered the study with a mean BMI of 26.1 kg/m2. This
group experienced an increase in BMI during follow-up and
the mean BMI reached the obesity range (i.e. BMI C 30).
We named this group the ‘‘progressive weight gain’’ group.
The third group included 102 individuals (5.8 %) who ini-
tially started with an average BMI in the obese range (mean
BMI = 30.2 kg/m2). In this group, the average BMI
decreased to the overweight range and continued to decrease
for the next 10 years. The mean BMI eventually reached the
normal-weight range.We named this group the ‘‘progressive
weight loss’’ group (Fig. 2a).
Among 2184 subjects who did not develop CVD event
and were alive until the end of follow-up, the ‘‘CVD-free’’
group, the average BMI remained stable. In this group the
average BMI ranged from 25.0 to 25.9 kg/m2 during the
follow-up. Among 2194 subjects who died of other causes
during follow-up, the ‘‘non-CVD mortality’’ group, the
average BMI at the start of the follow-up (average
BMI = 25.8 kg/m2) was in the overweight range. This
group slightly lost weight during follow-up and just before
death their mean BMI was in the normal range (Fig. 2a).
While the analyses were performed in the total popu-
lation, to plot the trajectories of change in BMI and in other
cardio-metabolic risk factors, it was necessary to assume a
hypothetical individual with a predefined sex and age.
Therefore, the presented figures are sex specific. Figures 2
and 3 represent the trajectories for a hypothetical man of
65 years old. Similar trajectories for a hypothetical woman
of 65 years of age are shown in Figures S1 and S2 in the
Supplementary Material.
Trajectories of waist circumference
Trajectories of waist circumferences differed significantly
between the three groups (p\ 0.001 for all pairwise
comparisons) (Fig. 2b). The trajectories for the ‘‘progres-
sive weight loss’’ and ‘‘progressive weight gain’’ groups
broadly resembled the trajectories of BMI in these groups.
However, among individuals in the ‘‘stable weight’’ group,
we observed a slight increase in the mean waist circum-
ference during follow-up. The mean waist circumference in
the ‘‘CVD-free’’ and ‘‘non-CVD mortality’’ groups
decreased during follow-up (Fig. 2b).
Trajectories of blood pressure
Trajectories of systolic blood pressure among
‘‘stable weight’’, ‘‘progressive weight loss’’, and ‘‘pro-
gressive weight gain’’ groups were not significantly dif-
ferent (p C 0.208 for all pairwise comparisons). The
‘‘stable weight’’ and ‘‘progressive weight loss’’ groups had
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a mean systolic blood pressure between 130–142 mmHg
during follow-up. In the ‘‘progressive weight gain’’ group,
the average systolic blood pressure levels increased during
the follow-up from 120 mmHg to 138 mmHg before the
cardiovascular event (Fig. 2c).
Trajectories of diastolic blood pressure for all groups of
BMI were in the normal range during follow-up
(\80 mmHg). The average diastolic blood pressure tra-
jectory of the ‘‘progressive weight gain’’ group was sig-
nificantly higher (p = 0.012) than the ‘‘progressive weight
Table 1 Characteristics of
study participants at their first
clinical examination
Characteristics Total population (N = 6126)
Time before diagnosis/last visit (years) 14.7 (7.6, 18.3)
Women (%) 3787 (61.8)
Current smoker (%) 1439 (23.5)
Antihypertensive treatment (%) 1035 (16.9)
Anti-diabetic treatment (%) 240 (6.8)
Statin treatment (%) 575 (16.3)
Age (years) 68.8 ± 8.9
Glucose (mg/dl) 105.7 ± 24.2
Cholesterol (mg/dl) 226.6 ± 37.2
HDL cholesterol (mg/dl) 54.9 ± 15.6
Systolic blood pressure (mmHg) 139.3 ± 22.1
Diastolic blood pressure (mmHg) 73.9 ± 11.4
Body mass index (kg/m2) 26.3 ± 3.7
Waist circumference (cm) 90.0 ± 11.1
HDL high density lipoprotein, CVD cardiovascular disease, n number
* Values are mean ± SD, numbers (percentages), or median (IQR)
 Fasting measurements of Lipids and glucose and treatment were available in the third, fourth and fifth
visits of the original Rotterdam Study cohort (N = 3529)
Fig. 2 Trajectories of body
mass index, waist
circumference, systolic and
diastolic blood pressure.
Trajectories for risk factors
during 22 years of follow-up
until diagnosis of CVD, death or
censoring from the study. The
figures represent a hypothetical
man of 65 years old.
Trajectories for blood pressure
represent a person on anti-
hypertensive treatment. Light
blue ‘‘stable weight’’ (including
87.8 % of CVD patients); dark
blue ‘‘progressive weight loss’’
(including 5.8 % of CVD
patients); red ‘‘progressive
weight gain’’ (including 6.4 %
of CVD patients); gray ‘‘CVD-
free’’; black ‘‘non-CVD
mortality’’ groups. Similar
trajectories for a hypothetical
woman of 65 years of age are
shown in Figure S1 in
Supplementary Material. (Color
figure online)
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loss’’ group. Similarly to the ‘‘progressive weight gain’’
group, the ‘‘stable weight’’ and the ‘‘CVD-free’’
groups experienced a modest increase in mean diastolic
blood pressure during follow-up. Compared to the
‘‘stable weight’’ and ‘‘progressive weight gain’’ groups, the
‘‘progressive weight loss’’ group had the lowest mean
diastolic blood pressure during follow-up. Among the
‘‘non-CVD mortality’’ group, the mean diastolic blood
pressure decreased during follow-up and before death
(Fig. 2d).
Trajectories of lipids and glucose
We found no differences in fasting total cholesterol levels
between the three groups of individuals who developed
CVD during follow-up (p C 0.059 for all pairwise com-
parisons). Overall, the trajectories of fasting total choles-
terol followed those of BMI for the ‘‘stable weight’’ and
‘‘progressive weight loss’’ groups. However, the ‘‘pro-
gressive weight gain’’ group showed a decrease in average
levels of total cholesterol. In this group, the mean total
cholesterol levels decreased from 218 mg/dl to 190 mg/dl
during follow-up. The average levels of total cholesterol
(mean: 200 mg/dl) were stable for the ‘‘CVD-free’’ group
(Fig. 3a). Average levels of HDL cholesterol for the three
groups of ‘‘stable weight’’, ‘‘progressive weight loss’’ and
‘‘progressive weight gain’’ were lower compared to the
‘‘CVD-free’’ group. The mean levels of HDL cholesterol
decreased significantly in the ‘‘progressive weight gain’’
and the ‘‘stable weight’’ groups during follow-up. The
decrease in mean HDL levels was more pronounced in the
‘‘progressive weight gain’’ group compared to the
‘‘stable weight’’ group (p\ 0.001) (Fig. 3b).
Trajectories of fasting glucose differed between the
three groups of ‘‘stable weight’’, ‘‘progressive weight loss’’
and ‘‘progressive weight gain’’ (p\ 0.001 for all pairwise
comparisons). The ‘‘stable weight’’ group had an average
fasting glucose level of 140 mg/dl, which remained
stable during follow-up. Among the ‘‘progressive weight
gain’’ group, the mean fasting glucose levels were fluctu-
ating (increasing and decreasing) over the entire follow-up.
For the ‘‘progressive weight loss’’ group we observed a
Fig. 3 Trajectories of fasting plasma glucose, total cholesterol, HDL
cholesterol, and predicted 10-year CVD risk. HDL cholesterol, high-
density lipoprotein cholesterol; ACC/AHA, American College of
Cardiology/American Heart Association; CVD: cardiovascular dis-
ease. Trajectories for risk factors during 15 years of follow-up until
diagnosis of CVD, death or censoring from the study. The
figures represent a hypothetical man of 65 years, on lipid- or
glucose-lowering treatment. Light blue ‘‘stable weight’’ (including
87.8 % of CVD patients); dark blue ‘‘progressive weight loss’’
(including 5.8 % of CVD patients); red ‘‘progressive weight gain’’
(including 6.4 % of CVD patients); gray ‘‘CVD-free’’; black ‘‘non-
CVD mortality’’ groups. Similar trajectories for a hypothetical
woman of 65 years of age are shown in Figure S2 in Supplementary
Material. (Color figure online)
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decline in mean levels of fasting glucose from 200 mg/dl to
120 mg/dl during follow-up (Fig. 3c).
Trajectories of estimated 10-year CVD risk
Figure 3d shows the 10-year predicted risk of CVD esti-
mated by the ACC/AHA Pooled Cohort Equations algo-
rithm [15]. Despite the differences in BMI trajectories, the
10-year predicted risk of CVD increased similarly during
follow-up for all 3 groups of CVD patients. However, the
‘‘progressive weight gain’’ group had significantly higher
mean 10-year predicted risk of CVD than the
‘‘stable weight’’ group (p\ 0.001). In the ‘‘progressive
weight loss’’ group, the mean predicted CVD risk increased
rapidly 10 years before the CVD diagnosis. The 10-year
predicted risk of CVD for the ‘‘CVD-free’’ group was
lower than the 10-year predicted CVD risk in all other
groups.
Other characteristics
Table 2 shows characteristics of the participants at the time
of CVD diagnosis for the ‘‘stable weight’’, ‘‘progressive
weight gain’’ and ‘‘progressive weight loss’’ groups; or at
the last examination for the ‘‘CVD-free’’ and ‘‘non-CVD
mortality’’ groups. Compared to the ‘‘CVD-free’’ group,
other groups were older and included more men. Individ-
uals in the ‘‘stable weight’’ group were less likely to
receive treatment for hypertension and lipids but more
likely to smoke compared to the other two groups of
‘‘progressive weight loss’’ and ‘‘progressive weight gain’’.
Interestingly, the proportion of participants with a family
history of MI or stroke was significantly lower in the
‘‘stable weight’’ group compared to the ‘‘progressive
weight gain’’ group.
Discussion
In our prospective population-based cohort study of mid-
dle-aged and older adults followed every 4 years for over
22 years, we examined the development of different BMI
trajectories prior to the diagnosis of CVD. By using latent
class trajectory analysis, we found three distinct groups of
BMI change among individuals who were diagnosed with
CVD during follow-up. The majority of individuals
(87.8 %) who developed CVD had stable BMI levels over
time. These individuals were classified into the
‘‘stable weight’’ group. A small group of individuals who
experienced CVD during follow-up (6.4 %), which we
refer to as the ‘‘progressive weight gain’’ group, showed a
progressive increase in their mean BMI level. The third
group of individuals with a CVD event (5.8 %), named the
‘‘progressive weight loss’’ group, experienced a decrease in
their mean BMI level during follow-up. Our analysis
revealed different patterns of change in other cardio-
Table 2 Characteristics of study participants at the time of the diagnosis for the three groups with cardiovascular disease or at last visit for the
groups without cardiovascular disease (N = 6126)
Characteristics* Individuals developing cardiovascular disease during follow-up
(n = 1748)
Individuals free of CVD during
follow-up (n = 4378)
Stable weight
(n = 1534)
Progressive weight
gain (n = 112)
Progressive weight
loss (n = 102)
CVD-free
(n = 2184)
Non-CVD mortality
(n = 2194)
Age at diagnosis/last contact
(years)
75.7 ± 8.1 75.6 ± 7.3 79.4 ± 8.3 75.1 ± 7.1 77.2 ± 8.0
Women (%) 868 (56.6) 75 (67.0) 66 (64.7) 1496 (68.5) 1282 (58.4)
Ever smoker (%) 925 (60.3) 59 (52.7) 49 (48.0) 885 (40.5)§ 1202 (54.8)
Ever on antihypertensive treatment
(%)
391 (25.5) 58 (51.8) 47 (46.1) 662 (30.3)§ 570 (26.0)§
Ever on anti-diabetic treatment (%) 141 (9.2) 18 (16.1) 15 (14.7) 170 (7.8)§ 143 (6.5)§
Ever on statins treatment (%) 133 (8.7) 26 (23.2) 14 (13.7) 460 (21.1) 145 (6.6)§
Family history for myocardial
infarction or stroke (%)
845 (55.1) 76 (67.9) 62 (60.8) 1232 (56.4)§ 1143 (52.1)§
CVD cardiovascular disease, n number
* Values are mean ± SD or numbers (percentages)
 Significantly different from stable weight group (p for the difference\0.05)
 Significantly different from progressive weight loss group (p for the difference\0.05)
§ Significantly different from progressive weight gain group (p for the difference\0.05)
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metabolic risk factors including waist circumference, HDL
cholesterol, and glucose between the identified BMI tra-
jectories. This finding further highlights that CVD is a
heterogeneous disease with different pathophysiological
pathways.
In general, the use of BMI as an accurate anthropo-
metric measure in association with CVD and mortality
among the elderly population has been challenged [19–
21]. Recent data among middle-aged and elderly popula-
tions has demonstrated that the magnitude of relationship
between elevated BMI levels and CVD weakens with age
[22]. However, most of studies classified BMI into pre-
defined categories which are currently debatable in rela-
tion to mortality [23]. Such an approach may also cause
misclassification of individuals, especially those close to
the cut-points for classification [24]. Instead of studying
changes in pre-defined BMI categories, we chose to define
subgroups of BMI change over time using latent class
trajectory analysis. This type of statistical method is useful
to explore heterogeneous growth patterns that would not
be identified using conventional methods. Indeed, latent
class trajectory analysis is more flexible, because it models
group-specific average patterns of change in BMI during
follow-up. Our latent class trajectory analysis indicated
that among the majority of individuals who developed
CVD during the follow-up, the mean BMI levels remained
fairly stable (the ‘‘stable weight’’ group). Overall, within
the ‘‘stable weight’’ group, the mean values for other
cardio-metabolic risk factors also remained fairly
stable overtime and their levels were mostly within the
normal clinical range. In this group, we only observed a
slight increase in the mean waist circumference and a
decrease in mean HDL cholesterol levels before the CVD
diagnosis. However, the predicted 10-year CVD risk,
which combines several cardio-metabolic risk factors into
a single risk score [15], showed an increase among the
‘‘stable weight’’ group, indicating that this subgroup was
at high risk for developing CVD. This finding highlights
that BMI is not a good predictor of CVD risk among
middle-aged and elderly individuals [19, 22] and that a
combination of multiple cardio-metabolic risk factors
should be considered [15, 18].
The second group of individuals who developed CVD
during follow-up, the ‘‘progressive weight gain’’ group,
had a mean BMI level in the range of class II obesity
(35–40 kg/m2) at the time of CVD diagnosis. During fol-
low-up, this group showed an increase in mean waist cir-
cumference, a decrease in mean HDL cholesterol levels,
and a fluctuating pattern in fasting glucose levels. Previous
studies, based on a single-time measurement, have high-
lighted that waist circumference could play a specific role
in insulin resistance and dyslipidemia [25]. The findings of
our study, using multiple measurements over time, give
further support to this premise by showing that the increase
in waist circumference was accompanied by decrease in
HDL cholesterol levels during follow-up. Furthermore, we
also observed a fluctuating pattern in fasting glucose levels
among the ‘‘progressive weight gain’’ group in our study.
Whether this variability in glucose levels can be attributed
to an increase in BMI levels or waist circumference needs
further investigation. However, recent evidence points
towards the involvement of blood glucose fluctuation in the
development of vascular injury in diabetes [26]. It has been
demonstrated that fluctuations in blood glucose levels can
increase oxidative stress in type 2 diabetes mellitus patients
[27], which results in cell dysfunction and tissue injury.
The ‘‘progressive weight gain’’ group may therefore carry a
large cardio-metabolic burden.
In young adults, weight loss is beneficial and is viewed
as a positive response to lifestyle modification or medical
treatment. However, among the elderly, weight loss has
been associated with a high risk of mortality [17, 21, 28].
Our study comprised middle-aged and elderly individuals.
Among the 3 identified BMI trajectories in our study, one
distinct group showed a decline in mean BMI during fol-
low-up (the ‘‘progressive weight loss’’ group). In this
group, we observed a decrease in mean waist circumfer-
ence as well as decreases in mean fasting glucose levels
during follow-up. Despite the decreases in the mean levels
of some cardio-metabolic risk factors, the predicted
10-year CVD risk showed an increase among the ‘‘pro-
gressive weight loss’’ group, demonstrating that this sub-
group was at high risk for developing CVD. Similarly,
among the group that did not develop CVD event but died
of other causes (the ‘‘non-CVD mortality’’ group), the
average BMI levels declined before death.
In our study, we were able to assess the medication data
for all BMI subgroups. Interestingly, we found that the
‘‘progressive weight gain’’ group had the highest propor-
tion of treatment for hypertension and hyperlipidemia.
Remarkably, the trajectories of systolic blood pressure and
total cholesterol in the ‘‘progressive weight gain’’ group
were not significantly different from the ‘‘stable weight’’
group. Moreover, although a bit more pronounced in the
‘‘progressive weight gain’’ group, the predicted 10-year
CVD risk increased in all 3 groups of ‘‘stable weight’’,
‘‘progressive weight gain’’ and ‘‘progressive weight loss’’
during follow-up, exceeding the clinical threshold for
treatment. This may suggest that the overweight and obese
individuals gaining weight over time are more likely to be
screened for CVD and subsequently receive medication.
Notably, the ‘‘progressive weight gain’’ group only con-
stituted a small proportion (around 6 %) of participants
developing CVD events in our study. Therefore, treating
this group has a small impact on decreasing the overall
burden of CVD in total population.
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Strengths of the current study include the prospective
study design, large sample size, very long follow-up time,
and availability of repeated measurements for BMI toge-
ther with detailed data on cardio-metabolic risk factors and
medication use over time. These all facilitated the analysis
to create the latent classes and to estimate the trajectories
of traditional cardio-metabolic risk factors. Our study
overcomes the limitation of previous studies classifying
BMI into pre-defined categories which is debatable among
the elderly population in association with mortality [23].
Our statistical approach allows for exploring heterogeneous
growth patterns that would not be identified using con-
ventional methods. However, one disadvantage of latent
class analysis is that it creates subgroups with very dif-
ferent sizes [29]. Therefore, comparison of subgroups, in
terms of statistical power, can be difficult. Moreover, while
the participants in the same group tend to be homogenous,
some individual variation around the group mean is
allowed.
In conclusion, latent class trajectory analysis identified
three distinct patterns of BMI development prior to a CVD
event. The majority of individuals who developed CVD
had a stable weight during follow-up, suggesting that BMI
alone is not a good indicator for identifying middle-aged
and elderly individuals at high risk of CVD. Moreover, the
accompanying trajectories of waist circumference, HDL
cholesterol, and glucose differed between the identified
BMI subgroups, further highlighting that CVD is a
heterogeneous disease with different pathophysiological
pathways.
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